Profound Medical Corp

Profound Medical Corp. develops, manufactures and markets therapeutic platforms that combine real-time magnetic resonance imaging with directional and focused ultrasound technology for incision-free ablation of diseased tissue. The firm's platforms offer clinicians and patients incision-free alternatives to current standards of care, which could include traditional surgery or radiation therapy. Its products include TULSA-PRO and Sonalleve. The company was founded in 2008 and is headquartered in Mississauga, Canada.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Profound Medical Corp reports revenue growth and eyes expansion opportunities

Profound Medical Corp's Q4 2022 performance reflects revenue growth driven by recurring revenue and progress in key trials and applications.
While facing financial challenges and capacity constraints, the company's strengths lie in the growing adoption of TULSA-PRO and AI software innovations.
Opportunities for growth include pending trial results, AI software value proposition, and expansion plans in key states, positioning the company for future success.

Profound Medical Corp reports revenue growth and expansion opportunities

Profound Medical Corp shows promising revenue growth and recurring revenue increase in Q1 2023, driven by the success of TulsaPro and Sonalleve platforms. While facing challenges in managing expenses and reducing backlog, the company is focused on expanding installations and preparing for reimbursement to drive future growth.

Profound Medical Corp reports revenue growth amidst widened net loss

Profound Medical Corp reported strong revenue growth in Q2 2023, driven by their innovative treatment technologies.
While facing challenges with a widened net loss, the company's focus on operational efficiency and market expansion presents growth opportunities.
Future prospects include expanding the install base, improving margins, and leveraging AI technology to drive profitability and market reach.

Profound Medical Corp reports revenue growth amidst profitability challenges

Profound Medical Corp's Q3 2023 performance showed revenue growth and strong cash reserves, but challenges persist in managing expenses and achieving profitability.
The company's strengths include recurring revenue growth, strategic partnerships, and innovative developments in AI applications for medical procedures.
Addressing operational challenges and seizing opportunities in market expansion and technology advancements will be crucial for future success.

Profound Medical Corp reports robust revenue growth and strategic focus

Profound Medical Corp's Q4 2023 performance showed strong revenue growth and strategic focus on TULSA's market adoption and innovation.
While facing challenges with patient reimbursement and payment models, the company aims to capitalize on opportunities for expansion and increased utilization.
By emphasizing customer retention, technology advancement, and market awareness, Profound Medical Corp positions itself for sustained growth and success in the prostate cancer treatment market.

Profound Medical Corp reports Q1 growth, eyes TULSA technology opportunities

Profound Medical Corp's Q1 2024 performance reflects a mix of revenue growth and operational improvements.
The company's focus on innovative TULSA technology and strategic collaborations positions it for future success.
While facing financial challenges and high operating expenses, Profound's growth outlook remains positive.
Navigating reimbursement rates and optimizing revenue streams are key priorities for sustainable growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Profound Medical Corp. engages in developing, manufacturing, and marketing of therapeutic platforms that combine real-time magnetic resonance imaging with directional and focused ultrasound technology for incision-free ablation of diseased tissue. Its platforms offer clinicians and patients incision-free alternatives to current standards of care, which could include traditional surgery or radiation therapy. Its products include TULSA-PRO and Sonalleve. The company was founded in 2008 and is headquartered in Mississauga, Canada.

TORONTO, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported financial results for the second quarter ended June 30, 2021.

Profound Medical Announces Second Quarter 2021 Financial Results

PROFOUND MEDICL (PROF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PROFOUND MEDICL (PROF) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

TORONTO, July 22, 2021 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, announced today that management will participate in A.G.P.'s Virtual MedTech Summer Conference on Thursday, July 29, 2021.

Profound Medical to Participate in A.G.P.'s Virtual MedTech Summer Conference

TORONTO, July 15, 2021 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its second quarter 2021 financial results after market close on Wednesday, August 4, 2021.

Profound Medical to Release Second Quarter 2021 Financial Results on August 4 – Conference Call to Follow

TORONTO, May 25, 2021 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX: PRN; NASDAQ: PROF) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, announced today that management will participate in two investor conferences in June.

Profound Medical to Participate in June Investor Conferences

TORONTO, May 19, 2021 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX: PRN; NASDAQ: PROF) (“Profound” or the “Company”) is pleased to announce the voting results from its Annual Meeting of Shareholders that was held today (the “Meeting”). A total of 11,810,287 common shares, representing 58.044% of the common shares outstanding, were represented in person and by proxy at the Meeting.

Profound Medical Announces Voting Results from the 2021 Annual Meeting of Shareholders and Management Changes

Profound Medical's (PROF) CEO Arun Menawat on Q1 2021 Results - Earnings Call Transcript

TORONTO, May 12, 2021 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported financial results for the first quarter ended March 31, 2021.

Profound Medical Announces First Quarter 2021 Financial Results

Analysts Estimate PROFOUND MEDICL (PROF) to Report a Decline in Earnings: What to Look Out for

TORONTO, April 21, 2021 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its first quarter 2021 financial results after market close on Wednesday, May 12, 2021.

Profound Medical to Release First Quarter 2021 Financial Results on May 12 – Conference Call to Follow

TORONTO, April 14, 2021 (GLOBE NEWSWIRE) --  Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, announced today that management will present an update on the Company's business at the 2021 Bloom Burton & Co. Virtual Healthcare Investor Conference on Wednesday, April 21, 2021 at 1:30 p.m. ET.

Profound Medical to Participate in the 2021 Bloom Burton & Co. Virtual Healthcare Investor Conference

TORONTO, March 03, 2021 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, announced today the appointment of Cynthia Lavoie Ph.D., MBA, to its Board of Directors.

Profound Medical Announces the Appointment of Cynthia Lavoie to its Board of Directors

Profound Medical Corp. (PROF) CEO Arun Menawat on Q4 2020 Results - Earnings Call Transcript

PROFOUND MEDICL (PROF) delivered earnings and revenue surprises of -40.74% and -4.95%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

PROFOUND MEDICL (PROF) Reports Q4 Loss, Lags Revenue Estimates

TORONTO, March 02, 2021 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported financial results for the fourth quarter and full year ended December 31, 2020.

Profound Medical Announces Fourth Quarter and Full Year 2020 Financial Results

TORONTO, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, announced today that management will participate in two investor conferences in March.

Profound Medical to Participate in March Virtual Investor Conferences

TORONTO, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, announced today that management will participate in a fireside chat at the BTIG Virtual MedTech, Digital Health, Life Science and Diagnostic Tools Conference on Thursday, February 18, 2021 at 12:00 p.m. ET.

Profound Medical to Participate in the BTIG Virtual MedTech, Digital Health, Life Science and Diagnostic Tools Conference

TORONTO, Feb. 09, 2021 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its fourth quarter and full year 2020 financial results after market close on Tuesday, March 2, 2021.

Profound Medical to Release Fourth Quarter and Full Year 2020 Financial Results on March 2 – Conference Call to Follow

Kaleyra

Telos

I have put an emphasis on value in 2021; however, I am not sitting still in my aggressive portfolio. I have added 2 new positions and added to a third. All 3 companies look to benefit from a return to normalcy or special events in 2021 and possess growth qualities and TAMs that could lead to exponential growth.

3 Under-The-Radar, Aggressive Growth Gems I Am Adding In 2021

TORONTO, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced preliminary unaudited revenues for the fourth quarter and full year 2020. Profound is providing this information due to the significant lag time between planned investment community meetings to be held in connection with, among other investor events, the 39th Annual J.P. Morgan Healthcare Conference, and its expected reporting of final 2020 results in March 2021.

Profound Medical Announces Preliminary Unaudited Fourth Quarter and Full Year 2020 Revenues

TORONTO, Dec. 21, 2020 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging (“MRI”), thermal ultrasound and closed-loop temperature feedback control for the radiation-free ablation of diseased tissue, announced today that it has entered into a co-development agreement with GE Healthcare.

Profound Medical Signs Agreement with GE Healthcare to Expand Provider Access to TULSA-PRO®

TORONTO, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”) announced today that Sonalleve® has received U.S. Food and Drug Administration (“FDA”) approval under a Humanitarian Device Exemption (“HDE”) for the treatment of osteoid osteoma.

Profound Medical Receives FDA HDE Approval for Sonalleve®

TORONTO, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging (“MRI”), thermal ultrasound and closed-loop temperature feedback control for the radiation-free ablation of diseased tissue, announced today that Linda Maxwell, M.D., has resigned from its Board of Directors and Murielle Lortie, CPA, CA, has been appointed as Dr. Maxwell's successor, effectively immediately.

Profound Medical Announces Changes to its Board of Directors

Profound Medical has unique differentiators via their TULSA-PRO procedure that provide a breakthrough in an otherwise complex treatment domain. The company has faced headwinds from COVID-19 this year, but key collaborations with RadNet adds torque to the TULSA-PRO flywheel.

Profound Medical's TULSA-PRO: Potential For Remedial Breakthrough In Complex Segment

TORONTO, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), the only company to provide customizable, incision-free therapies which combine real-time Magnetic Resonance Imaging (“MRI”), thermal ultrasound and closed-loop temperature feedback control for the radiation-free ablation of diseased tissue, announced today that management will participate in three investor conferences in November.

News for Profound Medical Corp Stock (PROF)